Navigation Links
Vanda Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 5, 2010
Date:8/2/2010

ROCKVILLE, Md., Aug. 2 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced it will release results for the second quarter of 2010, on Thursday, August 5, 2010, before the market opens. A full text copy of the release will be disseminated at that time.

Mihael H. Polymeropoulos, M.D., President and Chief Executive Officer, will host a conference call to discuss the results at 10:00 AM ET on Thursday, August 5, 2010. Also participating on the call will be Stephanie R. Irish, Acting CFO. To participate in the conference call, dial the appropriate number below shortly before the 10:00 AM start time and ask for the Vanda Pharmaceuticals conference call hosted by Dr. Polymeropoulos.

The teleconference dial-in numbers are as follows:

Domestic callers 1-866-788-0544

International callers 1-857-350-1682

Participant Passcode 57802480

The conference call will be broadcast simultaneously and archived on the Company's website, www.vandapharma.com. Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Thursday, August 5, 2010, beginning at 1:00 PM ET and will be accessible until Thursday, August 12, 2010, at 5:00 PM ET. The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers. The access number is 89391430.

ABOUT VANDA PHARMACEUTICALS INC.:

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders.  For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

Company Contact:

Cristina Murphy

Communications Manager

Vanda Pharmaceuticals Inc.

(240) 599-4500

cristina.murphy@vandapharma.com


'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results
2. Vanda Pharmaceuticals Reports Second Quarter 2009 Results
3. Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
4. Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
5. Vanda Pharmaceuticals Reports First Quarter 2009 Results
6. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
7. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
8. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
9. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2010
10. Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients
11. Amira Pharmaceuticals Hits Two Development Milestones Related to FLAP Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... ... Implant Systems announced today that the two-level components for the Revolution™ Spinal System were ... components expand the capabilities of the system and allow Revolution™ to be utilized for ... company has seen significant sales growth in 1Q 2016, and the system is currently ...
(Date:4/28/2016)... , April 28, 2016 ... reports the Company,s CEO  was featured in an ... Enter When VCs Fear To Tread: http://www.lifescienceleader.com/doc/accelerators-enter-when-vcs-fear-to-tread-0001 ... magazine is an essential business journal ... from emerging biotechs to Big Pharmas. Their content ...
(Date:4/28/2016)... York, NY (PRWEB) , ... April 28, 2016 ... ... QuickSTAT has made significant investments in recruiting top industry experts, and expanding its ... Platform, which provides industry-leading tools for clients to manage their clinical trial projects. ...
(Date:4/27/2016)... ... , ... Shimadzu Scientific Instruments (SSI) will be showcasing a ... and Expo. Shimadzu’s high-performance instruments enable laboratories to test cannabis products for potency, ... by booth 1021 to learn how Shimadzu’s instruments can help improve QA/QC testing, ...
Breaking Biology Technology:
(Date:3/22/2016)... and SANDY, Utah , March ... operates the highest sample volume laboratory in ... and UNIConnect, leaders in clinical sequencing informatics and molecular ... of a project to establish the informatics infrastructure for ... NSO has been contracted by the Ontario Ministry ...
(Date:3/15/2016)... 2016 Yissum Research Development Company of ... of the Hebrew University, announced today the formation of ... of various human biological indicators. Neteera Technologies has completed ... private investors. ... of electromagnetic emissions from sweat ducts, enables reliable and ...
(Date:3/10/2016)... , March 10, 2016 ... new market research report "Identity and Access Management Market ... Audit, Compliance, and Governance), by Organization Size, by Deployment, ... 2020", published by MarketsandMarkets, The market is estimated to ... 12.78 Billion by 2020, at a Compound Annual Growth ...
Breaking Biology News(10 mins):